Analyses of Patient Diaries in the Netter-1 Study of 77LU-Dotatate Versus High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors

首页> 外文期刊>Pancreas >Analyses of Patient Diaries in the Netter-1 Study of 77LU-Dotatate Versus High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors

【24h】

Analyses of Patient Diaries in the Netter-1 Study of 77LU-Dotatate Versus High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors

机译：患有患者日记的患者日记研究77LU-DOTATATE与高剂量奥曲霉IN的研究中的研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pancreas》 |2020年第3期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Analyses of Patient Diaries in the Netter-1 Study of 77LU-Dotatate Versus High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors [J] . Pancreas . 2020,第3期

机译：患有患者日记的患者日记研究77LU-DOTATATE与高剂量奥曲霉IN的研究中的研究
2. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With Lu-177-Dotatate in the Phase III NETTER-1 Trial [J] . Strosberg Jonathan, Wolin Edward, Chasen Beth, Journal of Clinical Oncology . 2018,第25期

机译：在III期VETTER-1试验中使用Lu-177-177-乳腺癌治疗的患者健康相关的生活质量患者
3. QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors [J] . Strosberg Jonathan, Wolin Edward, Chasen Beth, Pancreas . 2018,第3期

机译：QOL改善患者患者患者患者患者中脑内神经内分泌肿瘤
4. ~(213)Bi-DOTATOC receptor targeted alpha-radionuclide therapy induces remission in neuroendocrine tumors refractory to beta-radiation - a first in human study [C] . Giesel FL, Kratochwil C, Bruchertseifer F, 8th International Conference on Isotopes 2014 . 2014

机译：〜（213）Bi-DOTATOC受体靶向的α-放射性核素疗法可诱导难于β辐射的神经内分泌肿瘤缓解-这是人类研究中的首次
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial [O] . Jonathan Strosberg, Edward Wolin, Beth Chasen, -1

机译：NETLu-1 III期临床试验中用177Lu-Dotatate治疗进行性中肠神经内分泌肿瘤患者的健康相关生活质量
7. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group [O] . Anja Rinke, Carmen Schade-brittinger, Klaus-jochen Klose, 2009

机译：安慰剂对照，双盲，前瞻性，随机研究奥曲肽LaR控制转移性神经内分泌中肠肿瘤患者肿瘤生长的影响：来自pROmID研究组的报告

Analyses of Patient Diaries in the Netter-1 Study of 77LU-Dotatate Versus High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors

著录项

相似文献

相关主题

期刊订阅